BioInvent International (BINV) Reports 83% Response in NHL and FDA Fast Track for BI-1808 in Q2 2026 Interim Update

BioInvent International (BINV) Reports 83% Response in NHL and FDA Fast Track for BI-1808 in Q2 2026 Interim Update →

BioInvent International AB (Nasdaq Stockholm: BINV), a clinical-stage immuno-oncology biotech headquartered in Lund, Sweden, released its interim report for Q2 and H1 2026, highlighting major clinical achievements in its two leading antibod…